Merck & Co., Inc. (NYSE:MRK) rose 0.94% during previous trade. Jefferies issued rating on the stock of Merck & Co., Inc. (NYSE:MRK) in a research note issued to investors on Jan-12-17, the stock received “Upgrade” rating from Neutral to Overweight. Additionally Morgan Stanley issued their verdict on the stock of the company, on record date of Jan-12-17the stock was “Upgraded” from Equal-Weight to Overweight besides that on Jan-12-17Merck & Co., Inc. (NYSE:MRK) was “Upgraded” by Guggenheim from Neutral to Buy. Furthermore on Dec-19-16 the stock was “Downgraded” by Jefferies from Hold to Underperform.
Merck & Co., Inc. (NYSE:MRK) shares ended last trading session at the price of $62.21 whereas mean value of price target most recently revised on 1/10/17. The price target estimates represents a standard deviation of 7.52. However brokerage recommendations suggests an ABR of 2 based on calls of 13 experts, where 7 brokers polls the stock a Strong Buy, 0 suggest the stock a Buy, 5 suggest Hold, 0 are rating the stock as Sell while 1 as Strong Sell.
The stock exchanged hands 24.89M shares versus average trading capacity of 10.99M shares, while its shares’ total market worth is $176.42B along with 2.76B outstanding shares. Merck & Co., Inc. (NYSE:MRK) shares were trading -4.24% below from the 52-week high price mark of $64.96 and +33.87% above from the 52-week price bottom of $46.47. However the company observed 52 week high price on 11/10/16 and witnessed 52 week low price on 02/08/16. The company’s price sits 2.47% above from its 50-day moving average of $60.73 and 6.05% far from the stock’s 200-day moving average which is $61.13. Merck & Co., Inc. (NYSE:MRK)’s price to sales ratio for trailing twelve month stands at 4.31, whereas its price to book ratio for most recent quarter sits at 3.93. However the company’s price to cash per share for most recent quarter stands at 13.07. Its price to free cash flow for trailing twelve months is 256.35.